These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 18406240)

  • 21. Polycystic ovary syndrome (PCOS) and hyperandrogenism: the role of a new natural association.
    Morgante G; Cappelli V; Di Sabatino A; Massaro MG; De Leo V
    Minerva Ginecol; 2015 Oct; 67(5):457-63. PubMed ID: 26491824
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The molecular signature of polycystic ovary syndrome (PCOS) theca cells defined by gene expression profiling.
    Wood JR; Ho CK; Nelson-Degrave VL; McAllister JM; Strauss JF
    J Reprod Immunol; 2004 Aug; 63(1):51-60. PubMed ID: 15284005
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Genetics of polycystic ovary syndrome.
    Mykhalchenko K; Lizneva D; Trofimova T; Walker W; Suturina L; Diamond MP; Azziz R
    Expert Rev Mol Diagn; 2017 Jul; 17(7):723-733. PubMed ID: 28602111
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Polycystic Ovary Syndrome.
    Azziz R
    Obstet Gynecol; 2018 Aug; 132(2):321-336. PubMed ID: 29995717
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Polymorphism in CYP11alpha and CYP17 genes and the etiology of hyperandrogenism in patients with polycystic ovary syndrome].
    Pérez MS; Cerrone GE; Benencia H; Márquez N; De Piano E; Frechtel GD
    Medicina (B Aires); 2008; 68(2):129-34. PubMed ID: 18499961
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A microsatellite polymorphism (tttta)n in the promoter of the CYP11a gene in Chinese women with polycystic ovary syndrome.
    Wang Y; Wu X; Cao Y; Yi L; Chen J
    Fertil Steril; 2006 Jul; 86(1):223-6. PubMed ID: 16764871
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Characterization of reproductive, metabolic, and endocrine features of polycystic ovary syndrome in female hyperandrogenic mouse models.
    Caldwell AS; Middleton LJ; Jimenez M; Desai R; McMahon AC; Allan CM; Handelsman DJ; Walters KA
    Endocrinology; 2014 Aug; 155(8):3146-59. PubMed ID: 24877633
    [TBL] [Abstract][Full Text] [Related]  

  • 28. 17-hydroxyprogesterone responses to gonadotropin-releasing hormone disclose distinct phenotypes of functional ovarian hyperandrogenism and polycystic ovary syndrome.
    Pasquali R; Patton L; Pocognoli P; Cognigni GE; Gambineri A
    J Clin Endocrinol Metab; 2007 Nov; 92(11):4208-17. PubMed ID: 17785360
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The molecular-genetic basis of functional hyperandrogenism and the polycystic ovary syndrome.
    Escobar-Morreale HF; Luque-Ramírez M; San Millán JL
    Endocr Rev; 2005 Apr; 26(2):251-82. PubMed ID: 15561799
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Role of the pentanucleotide (tttta)(n) polymorphism in the promoter of the CYP11a gene in the pathogenesis of hirsutism.
    San Millán JL; Sancho J; Calvo RM; Escobar-Morreale HF
    Fertil Steril; 2001 Apr; 75(4):797-802. PubMed ID: 11287037
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MicroRNAs related to androgen metabolism and polycystic ovary syndrome.
    Sørensen AE; Udesen PB; Wissing ML; Englund ALM; Dalgaard LT
    Chem Biol Interact; 2016 Nov; 259(Pt A):8-16. PubMed ID: 27270454
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development of polycystic ovary syndrome: involvement of genetic and environmental factors.
    Franks S; McCarthy MI; Hardy K
    Int J Androl; 2006 Feb; 29(1):278-85; discussion 286-90. PubMed ID: 16390494
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Polycystic Ovary Syndrome as a systemic disease with multiple molecular pathways: a narrative review.
    Carvalho LML; Dos Reis FM; Candido AL; Nunes FFC; Ferreira CN; Gomes KB
    Endocr Regul; 2018 Oct; 52(4):208-221. PubMed ID: 31517612
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of differentially expressed microRNAs in the ovary of polycystic ovary syndrome with hyperandrogenism and insulin resistance.
    Lin L; Du T; Huang J; Huang LL; Yang DZ
    Chin Med J (Engl); 2015 Jan; 128(2):169-74. PubMed ID: 25591557
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A more atherogenic serum lipoprotein profile is present in women with polycystic ovary syndrome: a case-control study.
    Valkenburg O; Steegers-Theunissen RP; Smedts HP; Dallinga-Thie GM; Fauser BC; Westerveld EH; Laven JS
    J Clin Endocrinol Metab; 2008 Feb; 93(2):470-6. PubMed ID: 18056772
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ovarian morphology and endocrine function in polycystic ovary syndrome.
    Tena G; Moran C; Romero R; Moran S
    Arch Gynecol Obstet; 2011 Dec; 284(6):1443-8. PubMed ID: 21243502
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hyperinsulinism and its interaction with hyperandrogenism in polycystic ovary syndrome.
    Sozen I; Arici A
    Obstet Gynecol Surv; 2000 May; 55(5):321-8. PubMed ID: 10804539
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Developmental origin of polycystic ovary syndrome - a hypothesis.
    Abbott DH; Dumesic DA; Franks S
    J Endocrinol; 2002 Jul; 174(1):1-5. PubMed ID: 12098657
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Androgen excess fetal programming of female reproduction: a developmental aetiology for polycystic ovary syndrome?
    Abbott DH; Barnett DK; Bruns CM; Dumesic DA
    Hum Reprod Update; 2005; 11(4):357-74. PubMed ID: 15941725
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Polycystic ovary syndrome: definition, aetiology, diagnosis and treatment.
    Escobar-Morreale HF
    Nat Rev Endocrinol; 2018 May; 14(5):270-284. PubMed ID: 29569621
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.